Drug profile

The FDA adverse-event record for Unspecified Gabapentin

92 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Gabapentin. See the species affected, top reactions, and outcomes below.

92
adverse-event reports
25.0%
death-coded share
Dog
most-reported species
23
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
92
Total Reports
23
Deaths Reported
25.0%
Death Rate

Active Ingredients

Unspecified Gabapentin

Administration Routes

OralUnknown

Species Affected

Dog 80
Cat 12

Most Affected Breeds

Retriever - Labrador 18
Shepherd Dog - German 10
Domestic Shorthair 9
Terrier - Bull - American Pit 6
Shepherd Dog - Australian 5
Crossbred Canine/dog 4
Siberian Husky 4
Collie - Border 3
Retriever - Golden 3
Setter - English 2

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 23
Death by euthanasia 18
Vomiting 15
Not eating 12
Intentional misuse 12
Abnormal radiograph finding 12
Ataxia 10
Urinary incontinence 10
Medication error NOS 10
Behavioural disorder NOS 9
Lack of efficacy - NOS 9
Falling 8

Outcome Breakdown

Ongoing
36 (39.1%)
Outcome Unknown
24 (26.1%)
Euthanized
18 (19.6%)
Recovered/Normal
9 (9.8%)
Died
5 (5.4%)

Unspecified Gabapentin Adverse Event Insights

92 reports name Unspecified Gabapentin; 23 recorded a death outcome (25.0% of reported events, not a population-level mortality rate). Active ingredient: Unspecified Gabapentin. Administration routes: Oral, Unknown.

By species: Dog (80 reports), Cat (12 reports). By breed: Retriever - Labrador (18), Shepherd Dog - German (10), Domestic Shorthair (9).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (23), Death by euthanasia (18), Vomiting (15), Not eating (12). Outcome, 92 coded reports: Ongoing leads at 39.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.